Mary Pine, PA
Physician Assistant · Sunnyside, WANPI 1649388588
Payments from drug & device makers
Across 213 payments — averaging $20.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1K
- Boehringer Ingelheim$621
- Lilly USA, LLC$488
- Pfizer$387
- Novo Nordisk$324
- Bayer$182
- plus $1K from 19 others
What the payments were for
- Food & beverage$4,347100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 55 | $1,158 |
| Boehringer Ingelheim | 32 | $621 |
| Lilly USA, LLC | 24 | $488 |
| Pfizer | 18 | $387 |
| Novo Nordisk | 16 | $324 |
| Bayer | 7 | $182 |
| AbbVie | 9 | $177 |
| Johnson & Johnson | 8 | $161 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 10 | $157 |
| Sumitomo Pharma America, Inc. | 6 | $137 |
| GSK | 5 | $105 |
| E.r. Squibb & Sons, L.L.C. | 4 | $65 |
| Novartis | 2 | $54 |
| Kyowa Kirin, Inc. | 3 | $52 |
| Otsuka America Pharmaceutical, Inc. | 2 | $48 |
| Merck | 3 | $46 |
| Shield Therapeutics Inc | 1 | $29 |
| Corium, LLC | 1 | $24 |
| Indivior Inc. | 1 | $21 |
| Phathom Pharmaceuticals, Inc. | 1 | $21 |
| Xeris Pharmaceuticals, Inc. | 1 | $20 |
| Ipsen Biopharmaceuticals, Inc | 1 | $19 |
| Supernus Pharmaceuticals, Inc. | 1 | $17 |
| Daiichi Sankyo Inc. | 1 | $17 |
| Antares Pharma, Inc. | 1 | $16 |
How this compares
$4,347 in reported general payments places this provider in the 95th percentile of 2,741 physician assistant providers in Washington.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 169 | $271,718 |
| JardianceEmpagliflozin | 54 | $91,234 |
| FarxigaDapagliflozin Propanediol | 66 | $81,227 |
| JanuviaSitagliptin Phosphate | 43 | $48,588 |
| OzempicSemaglutide | 37 | $44,700 |
| TrulicityDulaglutide | 37 | $43,875 |
| Bydureon BciseExenatide Microspheres | 33 | $36,984 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 33 | $32,035 |
| MyrbetriqMirabegron | 25 | $28,896 |
| XareltoRivaroxaban | 15 | $27,366 |
| EliquisApixaban | 34 | $27,157 |
| Nurtec OdtRimegepant Sulfate | 12 | $21,653 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 378 | $15,094 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 12 | $13,225 |
| Spiriva RespimatTiotropium Bromide | 12 | $6,724 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $488 | $315,593206 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $1,158 | $113,26299 claims |
| Boehringer IngelheimJardiance, Spiriva Respimat | $621 | $97,95866 claims |
| PfizerEliquis, Nurtec Odt | $387 | $48,81046 claims |
| MerckJanuvia | $46 | $48,58843 claims |
| Novo NordiskOzempic | $324 | $44,70037 claims |
| Johnson & JohnsonXarelto | $161 | $27,36615 claims |
| GSKTrelegy Ellipta | $105 | $13,22512 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,741 physician assistant providers in Washington.
Other physician assistant in Sunnyside
- Jill KandoraShoreline$437K
- Jeannette HartRichland$263K
- Lance KeckTacoma$162K
- Erinn KingSeattle$129K
- Christy VathSeattle$75K
- Scott TaylorMercer Island$71K
- Gina FragioneGraham$69K
- Regan BrownSpokane$56K
- Justin ChapinSeattle$40K
- Susan DuffyBellevue$23K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.